https://www.selleckchem.com/products/Y-27632.html
[This corrects the article DOI 10.21037/atm-21-310.]. Esophageal cancer responds poorly to conventional radiotherapy, chemotherapy, and/or surgery. Immunotherapy works by boosting the body's immune system, and preoperative immunotherapy combined with chemotherapy may increase the survival rate of patients with esophageal cancer. Here we further explore immunotherapy's role in treating borderline resectable (BR) esophageal squamous cell carcinoma (ESCC) by combining immunotherapy with chemotherapy. In this multicenter, randomized control
Like
Comment
Share
